JPRN-UMIN000029601
Completed
未知
Safety and efficacy of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status: a pilot study. - A pilot study of pembrolizumab as first-line treatment in non-small cell lung cancer patients with poor performance status
Conditionsnon-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Hiroshima University Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Pleural effusion, ascites or pericardial effusion requiring drainage 2\)Other cancers 3\)Symptomatic brain metastasis and meningitis 4\)With severe complication 5\)Interstitial pneumonia on CT 6\)Severe drug allergy 7\)Active autoimmune disease that has required systemic treatment 8\)Dementia 9\)Other conditions not suitable for this study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety and efficacy of pembrolizumab as first-line treatment in elderly patients with non-small cell lung cancer: a pilot study.on-small cell lung cancerJPRN-UMIN000029602Department of Respiratory Internal medicine, Hiroshima Univestity Hospital35
Recruiting
Phase 2
Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPDNSCLC With COPDNCT05578222Tianjin Chest Hospital30
Recruiting
Phase 2
pembrolizumab plus axitinib trialrenal cell carcinomaJPRN-jRCT1061200062Takehiro Iawata7
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.253